Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC ConferenceESMO 2020 25 November, 2020 15:02
Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC ConferenceWCLC 2018 21 November, 2018 22:24